Investigators report success for Seaside's fragile X drug; Leukemia Society backs Constellation work on BET inhibitor;

Conversation on Twitter :

 @FierceBiotech: Slideshow: FierceBiotech's 2012 Fierce 15 at BioPharm America 2012. Slideshow | Follow @FierceBiotech

 @JohnCFierce: Novartis grabs a $665M option to buy sickle cell disease biotech--Selexys who? Story | Follow @JohnCFierce

 @RyanMFierce: MacroGenics banks $20M in potential $1.1B cancer drugs deal with Servier. Article | Follow @RyanMFierce

> Seaside Therapeutics, one of this year's Fierce 15 companies, has snagged important animal and human data that underscores the potential of its experimental therapy for fragile X syndrome, which can cause a form of autism. Scientists say that STX209 corrected genetic abnormalities engineered in mouse models of the disease. And among a small group, patients taking the drug registered a significant improvement on a key "social avoidance" measure. "We think this is a great drug," says co-author Dr. Randi Hagerman. Story

> Constellation Pharmaceuticals is getting $7.5 million from The Leukemia & Lymphoma Society to fuel work on a BET inhibitor for the treatment of hematologic malignancies. Release

> Shares of Sweden's Medivir jumped on the news that it's prepared to launch a mid-stage study of its hep C drug simeprevir. Story

Pharma News

 @FiercePharma: Bayer CEO tells Boston audience that pricing pressure threatens innovation--but U.S. isn't the problem. More | Follow @FiercePharma

> PhRMA eyes push for broader use of Part D approach. Article

> Survey: Docs less likely to prescribe drugs supported by pharma-funded trials. Report

> FDA: Boehringer Parkinson's med may boost heart failure risk. News

Medical Device News

 @FierceMedDev: We are in the FMD Fierce 15 final stretch. Winners revealed on Oct. 2 at AdvaMed 2012 and in FMD. Innovators all. More | Follow @FierceMedDev

 @MarkHFierce: In Mass., Dx, Rx and device companies can now cover modest meals and drinks, thanks to relaxed gift ban regs. Story | Follow @MarkHFierce

 @DamianFierce: Seattle startup Innovative Pulmonary has a new CEO and $10.6M in financing. News | Follow @DamianFierce

> Survey: Pharmas value tech when choosing Dx partners. More

> Conflicting arguments abound on the device tax's merits. Item

> Given Imaging soars after filing for Japanese approval. Article

Vaccines News

> Cardiff University works on anthrax vaccine for NATO. Item

> Emory snags $6M for HIV/AIDS vaccine research. Article

> Software magnate sinks $104M into vaccine research. More

> Obesity vaccine hits obstacle. Story

Pharma Manufacturing News

> Wholesaler McKesson faces new price-manipulation suit. Story

> Gerresheimer glass plant adds line, new furnace. Article

> Regulators OK Recipharm Monts filling expansion. More

> Florida man tied to cargo thefts ordered to forfeit $55M. News

And Finally… The Archives of Disease in Childhood reports that new research shows that obese kids "have less sensitive taste-buds than kids of normal weight." Release

 

Suggested Articles

Wedding Five Prime Therapeutics’ cabiralizumab to Bristol-Myers Squibb’s checkpoint inhibitor Opdivo has proved to be a bust in pancreatic cancer.

Sean Harper and Beth Seidenberg tell FierceBiotech how and why they set up their own VC firm, Westlake Village BioPartners.

Imara is looking to cap a good 2019 with an initial public offering in 2020. The rare disease biotech wants $86 million on the Nasdaq.